Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Hans Barle"'
Publikováno v:
Southern African Journal of Critical Care, Vol 30, Iss 2, Pp 45-50 (2014)
Objective. To determine the prevalence of dysmagnesaemia among patients admitted to a trauma intensive care unit (ICU) and to investigate whether dysmagnesaemia at admission correlated with a worse outcome. Methods. In this retrospective case study
Externí odkaz:
https://doaj.org/article/b6e1568b347b457a9e2aa87723663098
Publikováno v:
African Journal of Emergency Medicine, Vol 4, Iss 2, Pp 61-65 (2014)
To determine a correlation between lactate clearance within 48 h and survival in trauma patients at a Level I trauma centre in a developing country and compare to previous international lactate clearance studies. Methods: We conducted a retrospective
Externí odkaz:
https://doaj.org/article/4d37b1c317cc43e8aa99076e6b534037
Publikováno v:
PLoS ONE, Vol 12, Iss 8, p e0183073 (2017)
Septic shock is associated with high mortality. Aged and multimorbid patients are not always eligible for intensive care units. Norepinephrine is an accepted treatment for hypotension in septic shock. It is unknown whether norepinephrine has a place
Externí odkaz:
https://doaj.org/article/6b04537551a34a098e13fc3eb4a14328
Autor:
Karin, Strand, Hans, Barle
Publikováno v:
Lakartidningen. 113
Hypernatremia in ICU is common, both as a preexisting condition and acquired during intensive care. Hypernatremia increases mortality and morbidity as an increased length of a stay and increased risk of complications. Current treatment options of man
Autor:
Christina Ekström, Robert C. Baxter, Christer Möller, Michael Tally, Hans Olivecrona, Tomas J. Ekström, Hans Barle, Agneta Hilding, Björn Nyberg, Bo Angelin, Patrick J. Delhanty
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 84:553-560
We investigated the acute (4–5 h) and short-term (5 days) effects of GH treatment on hepatic messenger RNA (mRNA) levels of the genes for the insulin-like growth factors (IGFs), insulin-like growth factor binding protein-1, -2, and -3 (IGFBPs), and